Jump to navigation Jump to content

RoslinCT commits to Edinburgh BioQuarter with construction of a new Cell & Gene therapy manufacturing facility


RoslinCT – a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) – announces initiation of construction for the expansion of their new manufacturing centre at Edinburgh BioQuarter.

The new state of the art 1,600 m2 facility will operate to US and EU GMP standards and will become an innovative hub for the manufacture of cell and gene therapy products. This expansion accelerates the development and manufacturing capability of RoslinCT, promising to bring next-generation treatments to patients globally.

The new custom-designed facility will encompass five clean rooms, warehousing and offices for all supporting activities and will include a dedicated training lab that is set to be the new home of the company’s Training Academy. This new facility will also allow RoslinCT to grow their talent pool by creating new opportunities in order to shape an attractive, world-leading biotechnology hub. Growth plan covers a wide range of roles welcoming scientists and professionals from across the globe to join their dynamic team. RoslinCT has exciting and ambitious plans for growth and the expansion of the current facility will mark a new promising era for the company.

“As a leading CDMO in the field of cell and gene therapy, starting this expansion is a significant milestone in the growth of the business as we expand our global supply. Despite the Covid-19 pandemic the cell and gene therapy sector continues to grow and prosper. Beyond this new facility, we have ambitious plans for further expansion providing even greater capacity and increasing our gene therapy service offering. I am very proud of the RoslinCT team and how they have responded to recent challenges, enabling our start the expansion on site and continuing to support for our customers through clinical trials and beyond” said Janet Downie, CEO of RoslinCT

“ These state-of-the-art facilities will more than double our capacity to deliver game-changing cell and gene therapies for our customers and patients. Key to our success is our people and as we move through this phase of growth, we are developing a team and infrastructure to take the business forward. I am excited about providing such a great opportunity for our team and for attracting new talent to the business” said Kevin Bruce, Chief Operating Officer of RoslinCT.

Edinburgh BioQuarter welcomes this new development, and the services offered by RoslinCT  further strengthen BioQuarter as a leading global destination for healthcare delivery, ground-breaking medical research and life sciences innovation and entrepreneurship.

Find out more about RoslinCT